New Jersey-based Johnson & Johnson (JNJ) defended its testing and marketing. “Litigation does not change data,” a company spokesperson told Reuters. “Our analysis was designed to meet rigorous guidance on real-world evidence, and this legal action demonstrates Bayer’s obvious misunderstanding of methodological frameworks and real-world evidence principles.”
Bayer (BAYRY) and Johnson & Johnson (JNJ) did not immediately respond to Seeking Alpha’s request for comment.
More on Johnson & Johnson, Bayer
- Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
- Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
- Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention – Slideshow
- Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more
- Johnson & Johnson considering sale of orthopedics business – report